Profile data is unavailable for this security.
About the company
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. It provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. It is focused on branded generic businesses across India, Asia and Africa. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its business also consists of two verticals: the United States generics and the institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). Its cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin. Its subsidiaries include Ajanta Pharma (Mauritius) Limited, Ajanta Pharma USA Inc., Ajanta Pharma Philippines Inc., and Ajanta Pharma Nigeria Limited.
- Revenue in INR (TTM)44.91bn
- Net income in INR8.75bn
- Incorporated1979
- Employees7.84k
- LocationAjanta Pharma LtdAjanta House,, Charkop, Kandivli West,MUMBAI 400067IndiaIND
- Phone+91 2 266061000
- Fax+91 2 266061200
- Websitehttps://www.ajantapharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuland Laboratories Ltd. | 15.28bn | 2.80bn | 189.47bn | 1.65k | 67.75 | 13.65 | 55.14 | 12.40 | 217.98 | 217.98 | 1,191.20 | 1,081.52 | 0.847 | 2.14 | 4.85 | 9,273,565.00 | 15.50 | 9.25 | 20.03 | 12.71 | 52.14 | 47.81 | 18.30 | 11.99 | 1.40 | 31.56 | 0.0728 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Wockhardt Ltd | 29.49bn | -2.88bn | 190.86bn | 2.39k | -- | 5.31 | -- | 6.47 | -19.85 | -19.85 | 201.29 | 221.32 | 0.393 | 1.87 | 4.19 | 12,318,300.00 | -3.93 | -4.56 | -6.33 | -8.29 | 59.10 | 55.26 | -10.00 | -12.70 | 0.5677 | 0.247 | 0.3869 | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Alembic Pharmaceuticals Ltd | 63.57bn | 6.47bn | 204.00bn | 14.86k | 31.56 | 4.17 | 22.06 | 3.21 | 32.88 | 32.88 | 323.14 | 248.68 | 0.929 | 0.9366 | 5.43 | 4,278,678.00 | 9.45 | 10.72 | 13.32 | 14.25 | 73.84 | 65.98 | 10.17 | 12.47 | 0.8057 | 12.62 | 0.1791 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Concord Biotech Ltd | 10.86bn | 3.28bn | 208.31bn | 1.38k | 53.76 | 13.10 | 54.58 | 19.19 | 37.04 | 37.04 | 114.79 | 152.02 | 0.655 | 1.11 | 3.55 | 7,884,886.00 | 19.78 | -- | 21.82 | -- | 76.00 | -- | 30.20 | -- | 4.83 | 194.73 | 0.0022 | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Pfizer Ltd | 22.38bn | 6.18bn | 234.75bn | 1.72k | 37.99 | 6.26 | 34.58 | 10.49 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Emcure Pharmaceuticals Ltd | 72.56bn | 5.67bn | 242.76bn | 11.15k | 42.27 | 5.89 | 25.28 | 3.35 | 30.37 | 30.37 | 389.63 | 217.79 | 0.978 | 1.80 | 3.96 | 6,510,068.00 | 8.02 | 7.14 | 13.55 | 13.93 | 61.11 | 59.29 | 8.20 | 7.81 | 0.9549 | 5.25 | 0.2165 | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| Natco Pharma Ltd. | 45.61bn | 19.45bn | 246.23bn | 4.02k | 12.66 | 3.44 | 11.54 | 5.40 | 108.58 | 108.58 | 254.65 | 399.19 | 0.6291 | 0.8928 | 3.57 | 11,356,080.00 | 26.82 | 12.33 | 30.85 | 14.25 | 85.47 | 73.05 | 42.63 | 25.16 | 4.19 | 108.70 | 0.0283 | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
| Laurus Labs Ltd | 50.53bn | 1.31bn | 263.73bn | 6.01k | 201.06 | 6.38 | 48.37 | 5.22 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| J B Chemicals and Pharmaceuticals Ltd | 37.11bn | 6.11bn | 264.35bn | 5.31k | 44.27 | 8.23 | 34.40 | 7.12 | 38.45 | 38.45 | 233.33 | 206.82 | 0.9481 | 2.59 | 4.85 | 6,987,882.00 | 15.61 | 15.77 | 18.62 | 18.89 | 66.26 | 61.18 | 16.47 | 16.06 | 2.20 | 27.53 | 0.0303 | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Gland Pharma Ltd | 58.90bn | 6.92bn | 294.41bn | 4.22k | 42.57 | 3.35 | 27.38 | 5.00 | 41.98 | 41.98 | 357.57 | 533.41 | 0.5567 | 1.28 | 4.11 | 13,967,630.00 | 6.54 | 13.23 | 7.65 | 14.56 | 60.30 | 55.58 | 11.74 | 22.92 | 3.14 | 33.11 | 0.0358 | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Suven Pharmaceuticals Ltd | 9.61bn | 2.43bn | 324.43bn | 1.05k | 133.64 | 16.40 | 106.93 | 33.75 | 9.54 | 9.54 | 37.73 | 77.71 | 0.4156 | 1.52 | 5.99 | 9,136,501.00 | 10.50 | 23.17 | 11.50 | 26.20 | 61.42 | 58.85 | 25.27 | 33.21 | 4.00 | 29.50 | 0.0191 | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Pharma Ltd | 87.04bn | 453.30m | 324.55bn | 6.72k | 721.71 | 4.10 | 40.34 | 3.73 | 0.3407 | 0.3407 | 66.36 | 59.91 | 0.5799 | 1.40 | 4.88 | 12,954,040.00 | 0.302 | -- | 0.428 | -- | 63.69 | -- | 0.5208 | -- | 0.5603 | 7.49 | 0.3771 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Ajanta Pharma Ltd | 44.91bn | 8.75bn | 367.93bn | 7.84k | 42.35 | 10.01 | 36.36 | 8.19 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 85.33bn | 6.61bn | 399.22bn | 17.34k | 60.37 | 5.96 | 37.42 | 4.68 | 26.07 | 26.07 | 336.37 | 264.10 | 0.7483 | 1.12 | 4.78 | 4,922,642.00 | 5.88 | 10.33 | 9.00 | 13.52 | 67.36 | 59.16 | 7.85 | 12.25 | 1.32 | 25.33 | 0.129 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| GlaxoSmithKline Pharmaceuticals Limited | 35.60bn | 6.75bn | 401.43bn | 3.21k | 59.84 | 24.00 | 53.99 | 11.27 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Glenmark Pharmaceuticals Ltd | 122.48bn | -10.18bn | 413.80bn | 14.99k | -- | 4.90 | -- | 3.38 | -36.13 | -31.05 | 434.11 | 299.29 | 0.6951 | 1.53 | 4.04 | 8,171,082.00 | -5.64 | 1.02 | -8.51 | 1.43 | 65.64 | 59.47 | -8.11 | 1.43 | 1.00 | 2.56 | 0.1741 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Data as of Nov 22 2024. Currency figures normalised to Ajanta Pharma Ltd's reporting currency: Indian Rupee INR
14.25%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| UTI Asset Management Co. Ltd. (Investment Management)as of 31 Oct 2024 | 3.85m | 3.09% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Oct 2024 | 3.73m | 2.98% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 1.60m | 1.28% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Oct 2024 | 1.55m | 1.24% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Oct 2024 | 1.38m | 1.11% |
| Canara Robeco Asset Management Co. Ltd.as of 31 Oct 2024 | 1.28m | 1.03% |
| White Oak Capital Partners Pte Ltd.as of 30 Jun 2023 | 1.18m | 0.95% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 1.18m | 0.94% |
| Tata AIA Life Insurance Co. Ltd.as of 31 Oct 2024 | 1.09m | 0.87% |
| Invesco Asset Management (India) Pvt Ltd.as of 31 Oct 2024 | 961.66k | 0.77% |
More ▼
Data from 30 Jun 2023 - 14 Nov 2024Source: FactSet Research Systems Inc.
